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BackgroundAngiosarcomas represent less than 2% of all adult soft tissue sarcomas.
Prognostic factors and the role of (neo-) adjuvant treatments in the management of
localised angiosarcomas require further investigation. Methods We have conducted a
retrospective multicenter study (June 1980 to October 2009) of 107 patients with
localised angiosarcomas. All of the cases were centrally reviewed by a certified
pathologist. Univariate and multivariate analyses were conducted to identify
independent poor prognostic factors (PF). Overall survival (OS) and Local
Recurrence-Free Survival (LRFS) were estimated using the Kaplan–Meier method.
The effect of treatments was explored using the Cox model after adjusting for the PF.
Results The median age was 71 years. 22.4% and 62.6% developed an angiosarcoma
in pre-existing lymphoedema and within irradiated tissue respectively. The median
OS, LRFS and Disease Recurrence-Free Survival (DRFS) were 38.8, 27 and 36.1
months, respectively. In multivariate analysis, the following parameters influenced
the OS: lymphoedema (Hazard ratio (HR) = 2.0) and size >5 cm (HR = 1.5). After
adjustment to these PF, R0 margins was the only treatment parameter that
improving the OS (HR = 0.2). In the multivariate analysis, the LRFS was influenced
by an age >70 (HR = 1.8) and pre-existing lymphoedema (HR = 2.0). After
adjustment for these PF, R0 margins (HR = 0.5) and adjuvant radiotherapy (HR =
0.3) improved the LRFS. Conclusions Our results suggest the following points: (i)
pre-existing lymphoedema, tumour size and age >70 are probably the major
prognostic factors in patients with localised angiosarcomas; (ii) the achievement of
R0 margins is probably of major importance for improving the patient outcome and
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